Advertisement

Topics

Epithelial Ovarian Cancer Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

06:21 EDT 21 Jul 2017 | BioPortfolio Reports

DelveInsight's, Epithelial Ovarian Cancer Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Epithelial Ovarian Cancer. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Epithelial Ovarian Cancer. This report provides information on the therapeutic development for Epithelial Ovarian Cancer, dealing with all the pipeline drugs and comparative analysis at various stages covering all clinical, preclinical as well as discovery products. The report further contains details on dormant products and discontinued products. Therapeutic assessment of all the active products by route of administration and molecule type is also covered in this report.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Eisai
Eli
Exelixis
Genentech
Genor
Glycotope
Ignyta
ImmunoGen
Incyte
Innate
Johnson
Juno
Mabion
MabVax
MedImmune
Merck
Millennium
Mycenax
Novartis
Oasmia
OBI
Oncobiologics
Oncolix
Oncolytics
Otsuka
Oxford
OXiGENE
Pfizer
Pharma
Pharmacyclics
Prima
PsiOxus
Quest
Sanofi
Sanofi
Shenzen
Sotio
Synta
Tara
Tesaro
TetraLogic
Tyrogenex
VentiRx
ViiV
Vyriad
Epithelial Ovarian Cancer Pipeline Drugs
Epithelial Ovarian Cancer Pipeline Assessment
Epithelial Ovarian Cancer Pipeline Analysis
Epithelial Ovarian Cancer Drugs under Development
Epithelial Ovarian Cancer Discovery drugs
Epithelial Ovarian Cancer Preclinical drugs
Epithelial Ovarian Cancer Phase I drugs
Epithelial Ovarian Cancer Phase II drugs
Epithelial Ovarian Cancer Phase III Pipeline Drugs Assessment
Epithelial Ovarian Cancer Preregistration drugs
Epithelial Ovarian Cancer Molecules in pipeline

Original Article: Epithelial Ovarian Cancer Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000

NEXT ARTICLE

More From BioPortfolio on "Epithelial Ovarian Cancer Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $2000"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...